Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group study

G. M. Mills, S. Dahlberg, J. Cowan, B. A. Neilan, C. H. Gumbart, K. Hussein, C. A. Coltman

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Twenty-nine patients with heavily pretreated acute leukemia in relapse were treated with bisantrene (maximum dose 120 mg/m2/day x 5) in a phase II study. Twenty-seven of the 29 patients were evaluable for response, receiving a total of 53 courses of treatment. There were three complete remissions (11%) lasting 27, 107, and 115 days. One brief partial remission of 43 days was also seen for a total response rate of 15%. Toxicity was mainly limited to the expected myelotxicity with minimal nonhematologic toxicity seen. Although the complete remission rate is low, an antileukemic effect was seen in the majority of the patients treated. Sixty-one percent of the patients had at least a 50% decrease in the circulating blast count and 32% had at least a 50% decrease in the number of bone marrow blasts. We conclude that bisantrene does have an antileukemic effect, but that the optimal starting dose is not yet established.

Original languageEnglish (US)
Pages (from-to)507-510
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number6
DOIs
StatePublished - 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this